Drug intelligence / Profile preview

PF-05280014 + carboplatin + docetaxel

Development stage: Unknown
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

This is a combination therapy consisting of PF-05280014 (a trastuzumab biosimilar developed by Pfizer), carboplatin (a platinum-based chemotherapy agent), and docetaxel (a taxane chemotherapy agent). PF-05280014 is a monoclonal antibody that targets HER2 and is being developed as a biosimilar to Herceptin (trastuzumab).

Targets

DNATUBB (Tubulin (alpha and beta subunits))ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on PF-05280014 + carboplatin + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PF-05280014 + carboplatin + docetaxel.

Explore the full profile